This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Valerie Vanhooren
CEO at Ona Therapeutics


Valerie Vanhooren is the co-founder & CEO of ONA Therapeutics. At ONA Therapeutics, Valerie has spearheaded the development of first-in-class oncology therapeutics. Since co-founding ONA Therapeutics in 2019, the team has grown to over 20 members and secured over 30 million euros from a syndicate of international investors and public grants.

Previously, Valerie was head of research at ProteoDesign, a Princeton University spin-off currently known as SpliceBio, and project leader at Ablynx, a biologics company acquired by Sanofi engaged in the development of therapeutic Nanobodies®. At Ablynx, she led early-stage drug development projects in collaboration with multiple internationally operating pharmaceutical entities.

Valerie earned her doctorate at University of Ghent, Belgium, and carried out postdoctoral studies at the VIB-Ghent University. She has extensive expertise in immuno-oncology, inflammation and aging research and has published broadly in these fields.

Agenda Sessions

  • In collaboration with YVC Collective - In sync or offbeat: are the expectations of VCs and entrepreneurs aligned?

  • Talent is the new gravity: lessons from Barcelona